Caribou Biosciences: Underperform. The price already counts the cash

With both programs shut, the cash that reaches holders is what matters. At $0.4922 the market pays about 7% to 17% more than our estimate of that cash, and the board has not said it will return any.

CRBU Underperform, low conviction: the price sits at or above our estimate of cash that could reach holders, and a reverse merger looks likelier than a payout.

Rating: Underperform Low conviction
Horizon: 12 months, relative to US-listed biotech stocks
Price basis: $0.4922 on Oct 26, 2026, Nasdaq closing price (Stock Analysis quote page)

The call in brief

With both programs stopped, what matters for holders is the cash that reaches them plus whatever the assets fetch.
On filed numbers we estimate $0.42 to $0.46 a share of usable cash, and the market already pays $0.4922.
The board lists a merger, not a payout, and costs keep running until it decides.

How our ratings work

We rate Caribou Biosciences Underperform, with low conviction, over the next 12 months. The rating is set against the Nasdaq close of $0.4922 on October 26, 2026. Caribou is no longer a drug developer. It is a pot of cash with costs attached and a board choosing what to do with it. On the filed numbers, the price already sits at or above the cash we think could reach holders, and every month of the process spends some of it. Conviction is low because one good asset sale, or a decision to return cash, could beat the sector from a base this small.

How we got here

The pipeline is gone. On October 2, 2026, the board approved stopping both clinical programs, vispa-cel in lymphoma and CB-011 in multiple myeloma, cut staff, and hired Wedbush Securities to look at strategic alternatives. From here, what matters is what holders get from the balance sheet and any assets sold.
The usable cash is well below the headline. Caribou had $113.8 million of cash and investments at June 30, 2026. After restructuring costs, the lease liability and a quarter of spending, we estimate $0.42 to $0.46 a share on the 107.2 million shares outstanding at August 7 (arithmetic below).
The market pays more than that. At $0.4922, the market value is about $52.8 million, about 7% above the top of our range and about 17% above the bottom. Investors are already paying something for asset sales or a cheap exit from the leases.
The board has not said it will return cash. The 8-K lists a "merger, acquisition, business combination" among the options and says nothing about a distribution. It also keeps some staff for "transaction execution and business wind-down activities", so a wind-down is on the table too. In our view, a reverse merger would most likely leave holders with a minority stake in a different company.
Time is a cost. Staff, leases and adviser fees keep running until a deal closes, and the 8-K warns of further charges it cannot yet estimate.
So: we see more ways for per-share value to shrink than to grow from here, and the price leaves little room for them. That is an Underperform, held with low conviction.

What was stopped, and why it matters for value

The company says the data were strong. We read them more coldly. In June, Caribou reported phase 1 results from a single-arm study, with no control group. The headline figures cover only 27 second-line large B cell lymphoma patients, out of 63 treated in dose expansion, who received "optimized" cells at the 80 million-cell dose planned for phase 3. The response rate was 82%, the complete response rate 67% and median progression-free survival 17.1 months. The subgroup was defined as donors younger than 30 with at least two matched HLA alleles, the group that best fits the planned regimen, so the other 36 patients are not in the headline. The June quarter 10-Q lists the costs. In that 27-patient group, six patients (22%) had grade 3 or higher infections, five of 24 (21%) had grade 3 or higher prolonged cytopenias, and one (4%) had grade 3 or higher IEC-HS, an immune reaction. One death was related to the drug, from IEC-HS, and one more, from progressive multifocal leukoencephalopathy, was possibly related. A randomized phase 3 against standard care, ANTLER-3, would have been the first controlled test, and it was never funded. Phase 1 numbers from a chosen subgroup are not proof, and the board never had to find out whether they would be confirmed.

The board blamed money. In its words, the financing climate for allogeneic CAR-T "has made it increasingly challenging to secure the capital" for the programs. The phase 3 trial, ANTLER-3, had FDA alignment on a design of about 250 patients but was never funded.

For valuation, this cuts both ways. A program the company calls ready for phase 3, with RMAT, Fast Track and Orphan Drug designations, may fetch something from a buyer. But the board could not raise money for it from the market, which tells us what a buyer may be willing to pay.

Guidance we would now discount

On August 13, Caribou said its cash would fund its plan to the end of 2027. Fifty days later the board approved the wind-down. That runway covered only start-up work for ANTLER-3, so the guidance was narrower than it read. In the second quarter Caribou also sold 9,006,276 shares through its at-the-market program at an average of $2.03. Those buyers paid about four times today's price.

The cash, step by step

Cash, cash equivalents and marketable securities fell from $249.4 million at the end of 2024 to $113.8 million at June 30, 2026. Operating cash burn came down with job cuts, from $36.7 million in the first quarter of 2025 to $22.8 million in the second quarter of 2026.

Our arithmetic, using only filed figures:

Step	Per share, 107.2 million shares
Cash and investments at June 30, 2026: $113.8 million	$1.06
Less restructuring, $15 million to $19 million, and the $26.7 million lease liability	$0.64 to $0.67
Less one more quarter at the second-quarter burn of $22.8 million	$0.42 to $0.46

That third step assumes the September quarter ran at full cost, which fits a wind-down approved on October 2. It counts a little rent twice, because the burn figure includes about $1.2 million a quarter of lease payments. On the other side, the 8-K warns of costs it cannot yet estimate, from ending facility leases and other contracts. At the end of 2025, future lease payments before discounting came to $43.8 million, with a weighted average of 7.1 years left. A landlord can settle for less than the booked liability, or more.

What the price already assumes

	Amount
Shares outstanding at August 7, 2026 (10-Q cover)	107,207,513
Market value at $0.4922	about $52.8 million
Our estimate of cash that could reach holders	about $45.3 million to $49.3 million
What the market pays for everything else	about $3.5 million to $7.5 million

"Everything else" is the pipeline, the chRDNA patents, an exclusive license to the foundational CVC Cas9 patents with the right to sublicense (though Caribou has already granted exclusive field licenses to Intellia in human therapeutics and to Pioneer in some agricultural and industrial fields, which limits what a buyer gets), and licensing revenue of $1.5 million in the second quarter. We think a few million dollars for all of that is not unreasonable. The issue is that our cash figure is the best case for it, not the expected case, because it assumes the process ends now.

Bull case, bear case

Bull case (35%). The board sells vispa-cel or CB-011 for cash, licenses the patent estate, settles the leases cheaply, and distributes what is left. Or a reverse merger partner brings a story the market likes and the combined stock trades well. Either way, from a $52.8 million market value, holders could do better than the average biotech stock.

Bear case (65%). The board chooses a reverse merger. Holders own a minority of a new company, and the cash pays for someone else's pipeline. The process takes two or three quarters, costs keep running, and lease and contract charges come in at the high end. In our view the shares would then drift toward our cash arithmetic, or below it.

We weight the bear case more because the 8-K names deal structures first and has not mentioned a distribution, and because, in our view, boards in this position more often choose a deal than a payout.

Catalysts

10-Q for the quarter ended September 30, 2026. The real cash figure, against our $0.42 to $0.46 estimate.
An amended 8-K pricing the lease and contract charges. The 8-K says these were not yet estimable.
Any sale or license of vispa-cel, CB-011 or the patents. The price and whether it is paid in cash up front.
The strategic outcome. For a merger: the ownership split, any cash paid to holders before closing, and the vote.
The share price below $1. A Nasdaq bid-price notice is possible if it stays there.

Risks to our rating

We would move to Neutral if the board commits to returning cash, or if the third-quarter numbers and the lease charges come in better than our range. We would move to Outperform on an asset sale that adds meaningfully to cash per share. We would keep the rating if a reverse merger leaves holders with a small stake, and lift our conviction if the September cash falls below our estimate.

This is our opinion as of October 28, 2026, set against a share price of $0.4922 on October 26, 2026. It is not personal investment advice.

Sources

Every figure comes from the documents above. Chart values come from the company's financial statements as tagged in its SEC filings; derived values are labelled. If you find an error, tell us.